| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings GP/FP/Primary care
IM/Ambulatory care Gastroenterology Infectious disease
Key Words: helicobacter pylori • dyspepsia • metronidazole
METHODS
Design:
randomised controlled trial.
Allocation:
{concealed*}
.
Blinding:
unblinded.*
Follow up period:
5 weeks.
Setting:
ambulatory internal medicine clinics of 2 university affiliated hospitals in Canton, Ohio, USA.
Patients:
160 patients aged 
18 years (mean age 50 y, 57% women) who had dyspepsia and H pylori infection, a Glasgow Dyspepsia Severity Score (GDSS) 3 (score range 0–20), and a positive carbon 14 urea breath test result. Exclusion criteria included previous treatment of H pylori infection, pregnancy, personal or family history of gastrointestinal malignancy, antibiotic therapy in the previous 6 weeks, previous gastric surgery, and hepatic insufficiency.
Interventions:
1 day regimen of 2 tablets of bismuth subsalicylate, 262 mg each tablet, 4 times; 1 tablet of metronidazole, 500 mg, 4 times; amoxicillin suspension, 2 g, 4 times; and 2 tablets of lansoprazole, 30 mg each tablet, once (1 d regimen group; n = 80); or 7 day regimen of 1 tablet of clarithromycin, 500 mg, twice daily; 2 tablets of amoxicillin, 500 mg each tablet, twice daily; and 1 tablet of lansoprazole, 30 mg, twice daily (7 d regimen group; n = 80).
Outcomes:
eradication rates of H pylori, changes in GDSS score, and adverse effects.
Patient follow up:
94%.
MAIN RESULTS
All patients remained on their assigned treatment. 1 day therapy was not inferior to 7 day therapy for rates of eradication of H pylori (table
). The mean baseline GDSS score was 11 (standard deviation [SD] 3.4) in the 1 day regimen group and 10 (SD 3.3) in the 7 day regimen group. The groups did not differ for mean change from baseline in GDSS scores (both groups had a mean decrease from baseline of 7.5). None of the patients in either group reported intolerance to their treatment, and rates of side effects did not differ between groups.
|
Abstract and commentary also appear in ACP Journal Club.
FOOTNOTES
* See glossary. 
Information provided by author.
For correspondence: Dr F Whittier, Affiliated Hospitals at Canton, Canton, OH, USA. nancy.castro{at}csauh.com
Sources of funding: Aultman Health Foundation; TAP Pharmaceutical Products Inc.; Canton Medical Education Foundation.
New York University School of Medicine
New York, New York, USA
Dyspepsia is endemic and chronic. Most patients who are evaluated are diagnosed with non-ulcer or functional dyspepsia. Systematic reviews support a modest benefit of H pylori eradication in such patients, with perhaps 1 cure for every 15 patients treated.1 A Cochrane review concluded that the H pylori test and treat approach may be less expensive and just as effective as endoscopy based management in younger patients (<45 y) without alarm symptoms.2
Lara et al showed similar efficacy of 1 day and standard 7 day treatment in achieving H pylori eradication. Although dyspepsia symptoms improved, few patients had complete relief. If reproducible, a single day course would likely have great advantages in cost, convenience, and adverse effects. However, the 95% eradication rate in this study was much higher than that of previous studies, with rates ranging from 20–83%.3
We offer a few words of caution about this study. Most patients were >45 years old and, under current guidelines, should have endoscopy to exclude cancer. Moreover, 1 day therapy may be insufficient to heal ulcers in the 10–15% subset of patients with dyspepsia and underlying peptic ulcer disease. An important question remains the symptom recurrence rate over time. Longer follow up will be needed in future studies to address this.
The 1 day quadruple therapy, although intriguing, cannot be recommended based on current evidence. Until further studies are done with blinding to treatment allocation and longer follow up, we recommend a minimum 7 day course of H pylori treatment for patients with functional dyspepsia who choose the eradication option.
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
